Archives: Agenda

Leveraging peer-reviewed science to bridge the gaps in diagnoses to connect more patients with clinical trials

• We show how Patient and Site Burden Indexing helps quantify barriers to clinical trial participation, setting the foundation for smarter recruitment strategies
• How to go beyond the traditional site feasibility by combining real-world data from patient feasibility studies and patient population insights to identify and reach more patients
• Real-life case studies from our peer-reviewed papers demonstrating how data-driven, tailored campaigns highlight diagnosis gaps, improve patient reach, and de-risk enrollment outcomes

• The challenge
• The proposed solution
• What worked well
• Even better if…

• Learning from real-world case studies to accelerate biosimilar development and approval.
• Understanding the EMA’s reflection paper and its role in shaping regulatory expectations.
• Examining how a rapidly changing regulatory environment impacts development strategies.
• Assessing the implications for CROs in supporting sponsors through this transition.

• Designed for biotech: A Fit‑for‑Purpose FSP model, built with agility, to tailor to unique biotech needs
• Scales with innovation: Flexible resourcing that grows with evolving pipelines, addressing clinical trial complexities in an ever-changing clinical trial and geopolitical landscape
• Integrated expertise: Dedicated teams embedded as an extension of the sponsor with laser-focus on developing assets to time and quality
• Enabling progress: Supporting development from early stages through commercialization